Ricerca avanzata

Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2004 Giugno;46(2) > Panminerva Medica 2004 Giugno;46(2):141-8



Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Periodicità: Trimestrale

ISSN 0031-0808

Online ISSN 1827-1898


Panminerva Medica 2004 Giugno;46(2):141-8



Omalizumab: efficacy in allergic disease

Spector S.

University of California, Los Angeles, CA, USA

Asthma and allergic rhinitis are common conditions that have a substantial impact on patient quality of life, severely disrupting physical, emotional and social functioning. These diseases share many pathophysiological characteristics and recent research has provided evidence that a strong causal relationship exists between allergy and both asthma and allergic rhinitis. As a root cause of allergic diseases of the airways, immunoglobulin E (IgE) represents an appropriate target for the development of new therapies. Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody that has demostrated efficacy in allergic asthma and other IgE-related allergic illnesses. In three pivotal, placebo-controlled trials in patients with moderate-to-severe allergic asthma, omalizumab provided effective disease control, significantly reducing exacerbations while improving quality of life. Additionally, omalizumab reduced the need for unscheduled outpatient visits, emergency room visits and hospitalizations. Omalizumab was particularly useful as add-on treatment for patients with poorly controlled severe asthma. Similar benefits were reported in patients with seasonal or perennial allergic rhinitis. Omalizumab significantly improved disease symptoms and reduced the use of rescue antihistamines. In patients with concomitant asthma and perennial allergic rhinitis, omaliuzumab significantly prevented asthma exacerbations and improved quality of life compared with placebo. Taken together, these results suggest that omalizumab represents an important clinical advance in the management of allergic diesease.

lingua: Inglese


inizio pagina